The global adrenogenital syndrome treatment market is expected to reach USD 12.81 Billion in 2023 and is projected to exhibit a CAGR of 5.6% from 2023 to 2033. Natural treatments, minimally invasive surgeries, and new therapies are expected to drive growth.
Newborn screening programs are established in Austria to detect severe forms of AGS so that the affected children can receive appropriate treatment to avoid life-threatening salt-wasting crises. Swap therapy is one of the treatments administered as part of newborn screening programs. As the symptoms of milder forms, commonly called non-classical AGS, are late onset and milder compared to classical AGS, they often go undetected for a long time.
Surgically fixing abnormal genital appearances is further expected to enhance the market. Hormonal therapy is also used to replace the hormones that are not produced by the adrenal glands. On a daily basis, patients with chronic atopic diseases are administered corticosteroids or hydrocortisone. As a result of this treatment, the production of androgen will be normalized.
As this syndrome is highly prevalent among children and infants, the market is expected to substantially grow in the coming years. In the early stages of the condition, infants are injected with hormones, with the transition to orally administered hormones after 18 months. CAH patients who receive treatment are most likely to live a normal life. The survival rate for infants without treatment is usually less than six weeks.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2022) | USD 12.2 billion |
| Expected Market Value (2023) | USD 12.81 billion |
| Anticipated Forecast Value (2033) | USD 22.08 billion |
| Projected Growth Rate (2023 to 2033) | 5.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to a report from Future Market Insights (FMI), from 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5%. A primary concern of treating adrenogenital syndrome in the past was focusing on preventing or delaying the occurrence of the disease through hormonal and surgical therapies. For the treatment of hormone imbalances, the use of glucocorticoids, androgens, and estrogens has been used in the past to improve the balance of hormones. The symptoms of the condition were relieved by surgery to remove malignant tissue. More treatment options are now available to help patients cope with adrenogenital syndrome, and mental and emotional aspects of the disease are increasingly being addressed.
Developing better treatments for adrenogenital syndrome and reducing its associated risks will likely be the focus of government studies in the future. In order to improve the prognosis and quality of life for those living with the syndrome, new medications may be researched, hormone treatments may be prescribed, and lifestyle changes can be implemented.
Researchers may also conduct genetic tests to identify those at higher risk, and studies to better understand the disorder's causes. Researchers will ultimately strive to improve the quality of life of patients with androgenic syndrome through future government studies. The global demand for adrenogenital syndrome treatment is projected to increase at a CAGR of 5.6% during the forecast period between 2023 and 2033, reaching a total of USD 22.08 Billion in 2033.
Increased Prevalence of Adrenogenital Syndrome is Driving Market Growth
Due to improved diagnosis and awareness, adrenogenital syndrome has become increasingly prevalent over the past few years. In recent years, there has been an increase in the demand for treatment, which has been a contributing factor to the growth of the market as a whole. Due to government funding and support from large pharmaceutical companies, as well as collaborative research with large pharmaceutical companies, the global pharmaceutical market is expected to grow at a rapid pace over the next few years.
The growth in the incidence of chronic diseases and the rise in the geriatric population globally are driving the growth in the global adrenogenital syndrome market. Increasing healthcare expenditures, a rise in global per capita income, and improved healthcare infrastructure and government reimbursement programs are expected to drive the growth of the global adrenogenital syndrome market in the coming years.
Principal Consultant
New oral and intravenous drugs are being developed for the treatment of adrenogenital syndrome. The growing awareness of adrenogenital syndrome can be attributed to an increasing number of patients seeking medical attention, which can lead to more precise diagnoses and better treatment options for affected patients. Additionally, the growing demand for effective treatments and therapies is also driving the market.
The continuous development of new diagnostic and treatment methods is expected to further drive the market along with the introduction of new technology. Further, due to the increasing number of clinical trials and research activities being conducted in connection with adrenogenital syndrome, it is expected that the market will also grow at a rapid pace. As diagnostic tools continue to develop, adrenogenital syndrome will be diagnosed more quickly and accurately in the market. It will also contribute to the development of better medical practices. Thus, this could lead to improvements in image technology, genetic testing, and other methods of assessing health status in the future.
Ineffective Treatment and Side Effects Limit the Market
A lack of specialized endocrinologists with particular expertise in adrenogenital syndromes will restrain the growth of the market for this disease. Further, the high cost of hormonal therapy is also expected to hamper the growth of this market in the future. Moreover, the long-term side effects of hormone therapy and drugs are also expected to have a negative impact on the market's growth.
A lack of awareness about the therapies and the difficulty in finding an effective treatment regimen may be limiting the growth of the market. A further restraint on the market will be the risk of infection and other complications that may arise as a result of surgical procedures. If the syndrome is not treated properly or in a timely manner, there is a risk of recurrence or progression of the condition. An individual with this syndrome is at a higher risk of developing psychosocial problems associated with it, including body image issues and low self-esteem.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Treatment Programs for Adrenogenital Syndrome and Support to Surge the Market Demand
Adrenogenital syndrome treatment markets in North America are predicted to grow significantly during the forecast period. According to the forecast, the market is expected to account for 22% of overall demand.
The treatment of adrenogenital syndrome has made significant progress in North America. The adrenal glands are responsible for regulating hormone production in the body, which is suppressed by drugs like corticosteroids in the past. In spite of the fact that this was a useful treatment, there were frequent side effects associated with it, including weight gain, emotional disorders, and bone degeneration.
Natural treatments have become increasingly popular in North America. Supplements such as vitamin D and omega-3 fatty acids, as well as lifestyle changes, such as reducing stress, will also likely benefit the market. Further, it is becoming increasingly common to provide psychological assistance and emotional support programs to those who suffer from this chronic health condition. The treatment and diagnosis of patients are accompanied by counseling and support groups.
North American researchers are currently working on research to gain a better understanding of the causes of adrenogenital syndrome as well as developing new treatments that will relieve symptoms. The United States is fortunate to have a universal system of newborn screening for a condition called CAH, resulting from a deficiency in 21-hydroxylase. 80% of children who suffer from CAH are identified and treated early to prevent complications.
Growth in the Quality of Services and Infrastructure is Driving Demand for the Treatment of Adrenogenital Syndrome
Europe is forecast to hold the largest market for adrenogenital syndrome treatments. An estimated 15.6% of the total market in this region is devoted to treating adrenogenital syndrome. According to market projections, there will be substantial growth in the adrenogenital syndrome market in Europe during the forecast period of 2023 to 2033. Several countries, including the United Kingdom, France, Germany, Sweden, Netherlands, Italy, and Russia, are experiencing a large increase in population in the region, and that has fueled the growth of the market.
This growth can be attributed to the fact that the number of individuals in the region requiring advanced healthcare services is continuously increasing, helping to drive market growth. It is also predicted that players will strive to enhance the services they provide over the forecast period so that the market will grow in the near future. Health care has evolved and transformed rapidly over the past decade. There has been a significant shift in the healthcare industry across the EU region in recent years as a result of the penetration of digital technologies in a wide range of countries in the region. Aside from this, changes in the ways in which patients are diagnosed and treated are contributing to the transformation of the healthcare industry.
Drug Development for Glucocorticoids Drives Market Growth
Glucocorticoid drugs are projected to grow at a CAGR of 4.3% from 2023 to 2033. Adrenogenital syndrome is typically treated with glucocorticoids in order to reduce symptoms. Due to their overproduction of hormones, these drugs can reduce the number of hormones released, such as cortisol, which can increase production in patients with adrenogenital syndrome. An enlarged adrenal gland, a common symptom of the condition, can also be treated with glucocorticoids, which have the effect of reducing the size of the gland. Adrenogenital syndrome is often accompanied by inflammation, and glucocorticoids can help reduce inflammation if used appropriately.
In the future, glucocorticoid drugs could revolutionize the way adrenogenital syndrome is treated. Some cases may even improve with the use of glucocorticoids, leading to a complete resolution of symptoms. As a result, there will be growth in the market for these drugs in the near future.
A study has shown that glucocorticoids can reduce health problems associated with adrenogenital syndromes, like diabetes, hypertension, and central nervous system problems, by reducing corticoids in the body. Further research will be performed on glucocorticoids in the future, including their mechanisms of action, possible side effects, and interactions with other drugs.
Studies on Treating Adrenogenital Syndrome with Oral Medication will Increase
Based on the route of administration, the global market is segmented into oral, parenteral, intravenous, inhaled, and others. Based on the forecast period, it is estimated that the revenues for oral drugs will exceed USD 8.7 billion, which is an increase of 16%.
Adrenogenital syndrome has been treated with oral drugs for many years, and it is expected that this trend will continue to grow in the coming years. Medico-evolution brings new and improved treatments to patients as a result of medical advancements. There is still significant research going on with regard to these medications, in order to learn more about their effectiveness as well as their safety, which will lead to their wider usage in the future. With the increase in the number of treatment options available for adrenogenital syndrome, it is likely that oral drugs will continue to play a significant role in the treatment of this disorder in the future.
New start-ups in the adrenogenital syndrome treatment market include-
Praxgen Pharmaceuticals was founded in 2016 founded in the United States. Praxgen pharmaceuticals focus on generic prescription pharmaceuticals that improve patient health and create value for stakeholders by developing manufacturing and marketing high-quality generics. As a leading manufacturer of ophthalmics, injectables, topicals, and oral solids, the firm specializes in complex dosage forms and difficult manufacturing processes. Through partnerships and contract manufacturing, the company has facilities across North America and Asia, including research and development facilities in Princeton, NJ, and Monmouth Junction, NJ.
Zydus Pharmaceuticals a Cadila Healthcare Limited, is a global healthcare provider that is fully integrated. Healthcare expertise enables it to offer strong pharmaceutical value chain capabilities across the chain of pharmaceutical manufacturing. With a wide range of products ranging from pharmaceutical formulations to active pharmaceutical ingredients, animal healthcare products to wellness solutions, as well as offering comprehensive and complete healthcare solutions, Zydus has built a reputation among Indian pharmaceutical companies.
Vintage Labs is a Private Company, that was incorporated in 2002. VINTAGE LABS PRIVATE LIMITED resides in ROC-DELHI and is registered with the Registrar of Companies as a Non-Government company. Manufacturer of chemicals used in pharmaceutical manufacture, endocrine products, opium derivatives, antibiotics, basic vitamins, sulpha drugs, serums and plasmas, salicylic acid, its salts and esters; glycosides and vegetable, It comes under the division manufacturing of chemicals and pharmacotherapies.
Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demands. To ensure that end users are able to benefit from the use of new products and technologies, you must promote them to end users. By forming a strategic partnership, a company can increase the amount of production it can do as a result of an increase in its capacity.
Spruce Biosciences Inc. and Kaken Pharmaceutical Co. Ltd announced a licensing agreement to develop and commercialize Spruce's product candidate, tildacerfont, for treating congenital adrenal hyperplasia (CAH). Spruce will receive a D15 million upfront payment from Kaken as part of the agreement, and additional payments are pending upon reaching future development and commercial milestones. In addition to that, tiers of double-digit royalties will be paid on Japanese net sales. For all other geographies, Spruce will retain all rights to tildacerfont, while Kaken will develop and market it in Japan.
A new Phase 2 study from Neurorocrine Biosciences, Inc. is being presented demonstrating substantial reductions in adrenal androgens and androgen precursors in adolescent patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD). As part of its presentation in Hall A1, the company also provided information regarding patient preferences and treatment patterns for classic CAH.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 12.81 Billion |
| Market Value in 2033 | USD 22.08 Billion |
| Growth Rate | CAGR 5.6% |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Type, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Crystal Pharma; Monarch Pharmaceuticals, Inc.; Jubilant Cadista Pharmaceuticals Inc.; Pfizer CentreOne; Healthkey Lifescience Pvt. Ltd.; Zydus Pharmaceuticals; Praxgen Pharmaceuticals; Sandoz; Vintage Labs; Actavis, Inc. |
| Customization | Available Upon Request |
The hospital pharmacies hold high revenue potential.
The Adrenogenital syndrome treatment market is estimated to capture a valuation of USD 12.81 million in 2023.
The market is forecast to register a CAGR of 5.6% through 2033.
During 2018 to 2022, the market registered a CAGR of 5%.
The rising adoption of new treatments and therapies increases current market trends.
1. Executive Summary | Adrenogenital Syndrome Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Mineralocorticoids 5.2. Glucocorticoids 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Parenteral 6.3. Intravenous 6.4. Inhaled 6.5. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East and Africa (MEA) 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Crystal Pharma 16.2. Monarch Pharmaceuticals, Inc. 16.3. Jubilant Cadista Pharmaceuticals Inc. 16.4. Pfizer CentreOne 16.5. Healthkey Lifescience Pvt. Ltd. 16.6. Zydus Pharmaceuticals 16.7. Praxgen Pharmaceuticals 16.8. Sandoz 16.9. Vintage Labs 16.10. Actavis, Inc. 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Adrenogenital Syndrome Treatment Market
